Screener / SEC EDGAR /CIK 0001628171 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Revolution Medicines, Inc. RVMD

We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. 10-K, Item 1

Headquarters
Redwood City, CA
CEO
Mark A. Goldsmith
Next results
around Feb 24, 2027
Compare with peers Embed

RVMD among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 153 peers the company is above, not a score.

Compare
Operating margin: -853.0%, above 0% of 138 peers (their median 10.2%) OPERATING MARGIN -853.0% · above 0% Net margin: -946.8%, above 0% of 153 peers (their median 6.8%) NET MARGIN -946.8% · above 0% FCF margin: -729.3%, above 1% of 144 peers (their median 10.1%) FCF MARGIN -729.3% · above 1%
RVMD Peer median Below the median

What changed

37 new risk paragraphs. 10-K filed Feb 25, 2026 against Feb 26, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

8 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 8 checks found nothing to note

  • Cash from operations −$897.7M vs net income −$1.1B (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
5 more checks with nothing to note
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

37 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.

All 37 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    The Royalty Pharma Agreements place restrictions on our operating and financial flexibility. If we fail to comply with certain covenants in the Royalty Pharma Agreements, our financial condition and results of operations may be harmed. In June 2025, we entered into the Royalty Purchase Agreement with Royalty Pharma and the Loan…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    We are aware of several pharmaceutical companies developing products in the same class as our investigational products. See “Item 1. Business—Competition” for additional information regarding our competitors.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    The U.S. presidential administration has stated that it is pursuing a two-fold strategy to reduce drug costs in the U.S. While it is unclear whether and how these proposals will be implemented, they are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for any product…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    We have received a Commissioner’s National Priority Voucher (CNPV) from FDA for daraxonrasib, but we may not realize any benefit from our participation in the FDA’s CNPV Pilot Program, and any changes to or termination of the CNPV Pilot Program could delay or adversely affect development and review of our product candidates. In June…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$35.4M$11.6M$0$0
Net income−$248.7M−$436.4M−$600.1M−$1.1B
Operating cash flow−$224.4M−$350.6M−$557.4M−$897.7M
Free cash flow−$235.2M−$358.3M−$567.7M−$913.7M

Revenue, FY2018 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$0 in FY2025

FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

8 filings in the last 30 days · SEC EDGAR

All filings
3 more

About the company

Revolution Medicines, Inc., Redwood City, CA · from the 10-K filed Feb 25, 2026

We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens.

Headquarters
Redwood City, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVMD/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.